SOX2 utilizes FOXA1 as a heteromeric transcriptional partner to drive proliferation in therapy-resistant prostate cancer.

Saved in:
Bibliographic Details
Title: SOX2 utilizes FOXA1 as a heteromeric transcriptional partner to drive proliferation in therapy-resistant prostate cancer.
Authors: Phoenix JT; Department of Cancer Biology, Loyola University Chicago, Maywood, IL, USA.; Integrated Program in Biomedical Science, Biochemistry, Molecular and Cancer Biology, Loyola University Chicago, Maywood, IL, USA., Budreika A; Department of Cancer Biology, Loyola University Chicago, Maywood, IL, USA.; Integrated Program in Biomedical Science, Biochemistry, Molecular and Cancer Biology, Loyola University Chicago, Maywood, IL, USA., Schmeck DA; Department of Medicine, University of Minnesota, Masonic Cancer Center, Minneapolis, MN, USA., Kostlan RJ; Department of Cancer Biology, Loyola University Chicago, Maywood, IL, USA.; Integrated Program in Biomedical Science, Biochemistry, Molecular and Cancer Biology, Loyola University Chicago, Maywood, IL, USA., Ferrari MG; Department of Cancer Biology, Loyola University Chicago, Maywood, IL, USA., Young KS; Department of Cancer Biology, Loyola University Chicago, Maywood, IL, USA.; Integrated Program in Biomedical Science, Biochemistry, Molecular and Cancer Biology, Loyola University Chicago, Maywood, IL, USA., Rogers CS; Department of Cancer Biology, Loyola University Chicago, Maywood, IL, USA., Deegan CD; Department of Cancer Biology, Loyola University Chicago, Maywood, IL, USA.; Integrated Program in Biomedical Science, Biochemistry, Molecular and Cancer Biology, Loyola University Chicago, Maywood, IL, USA., Bienko MW; Department of Cancer Biology, Loyola University Chicago, Maywood, IL, USA., Bergom HE; Department of Medicine, University of Minnesota, Masonic Cancer Center, Minneapolis, MN, USA., Boytim E; Department of Medicine, University of Minnesota, Masonic Cancer Center, Minneapolis, MN, USA., Brown RM; Department of Pathology, University of Illinois at Chicago, Chicago, IL, USA., Walewicz JA; Department of Cancer Biology, Loyola University Chicago, Maywood, IL, USA., Bhagi SK; Department of Cancer Biology, Loyola University Chicago, Maywood, IL, USA., Ellis L; Center for Prostate Disease Research, Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center, The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, USA., Antonarakis ES; Department of Medicine, University of Minnesota, Masonic Cancer Center, Minneapolis, MN, USA., Drake JM; Department of Pharmacology, University of Minnesota, Minneapolis, MN, USA., Bawa PS; Center for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA, USA., Vellky JE; Department of Pathology, University of Illinois at Chicago, Chicago, IL, USA., Williams A; Department of Medicine, University of Chicago, Chicago, IL, USA., Rezine NM; Department of Pathology, University of Illinois at Chicago, Chicago, IL, USA., Rennhack JP; Department of Cancer Biology, Loyola University Chicago, Maywood, IL, USA., Fanning SW; Department of Cancer Biology, Loyola University Chicago, Maywood, IL, USA., Hwang JH; Department of Medicine, University of Minnesota, Masonic Cancer Center, Minneapolis, MN, USA., Szmulewitz RZ; Department of Medicine, University of Chicago, Chicago, IL, USA., Vander Griend DJ; Department of Pathology, University of Illinois at Chicago, Chicago, IL, USA., Kregel S; Department of Cancer Biology, Loyola University Chicago, Maywood, IL, USA.
Source: BioRxiv : the preprint server for biology [bioRxiv] 2025 Jul 19. Date of Electronic Publication: 2025 Jul 19.
Publication Type: Journal Article; Preprint
Journal Info: Country of Publication: United States NLM ID: 101680187 Publication Model: Electronic Cited Medium: Internet ISSN: 2692-8205 (Electronic) Linking ISSN: 26928205 NLM ISO Abbreviation: bioRxiv Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2692-8205
DOI:10.1101/2025.07.18.664790